Latest Articles

Publication Date
All News Scientific
Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment - TipRanks

Bayer’s New Study on Mirena: A Potential Game-Changer for Endometrial Hyperplasia Treatment TipRanks

Published: Oct. 27, 2025, 11:58 p.m.
Read Full Article
Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

Genmab’s New Phase 3 Study: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 11:43 p.m.
Read Full Article
BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks

BioNTech’s Promising Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 10:53 p.m.
Read Full Article
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - TipRanks

Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study TipRanks

Published: Oct. 27, 2025, 10:21 p.m.
Read Full Article
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks

Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 9:13 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal

Published: Oct. 27, 2025, 7:50 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Yahoo Finance

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Yahoo Finance

Published: Oct. 27, 2025, 7:33 p.m.
Read Full Article
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - Business Wire

CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer Business Wire

Published: Oct. 27, 2025, 7:33 p.m.
Read Full Article
Polygala fallax Hemsl. Suppresses Malignant Phenotypes of Ectopic Endometrial Cells via the LINC02381-miR-27a-3p-EGFR Axis and PI3K/Akt Signaling - Frontiers

Polygala fallax Hemsl. Suppresses Malignant Phenotypes of Ectopic Endometrial Cells via the LINC02381-miR-27a-3p-EGFR Axis and PI3K/Akt Signaling Frontiers

Published: Oct. 27, 2025, 5:08 p.m.
Read Full Article
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment - TipRanks

Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment TipRanks

Published: Oct. 27, 2025, 5:04 p.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!